Ringworm In People Of Color

identify the first patient

treated with stem cells

embryonic

21 year old who suffered a severe spinal cord injury after a car accident, received a revolutionary treatment.

by La Tercera - 07/04/2011
After the FDA last year approved the first treatment in humans with embryonic stem cells to cure people with paraplegia, the identity of the first patient to receive therapy had saved with total reserves. Until now.

This, as The Washington Post revealed that Timothy J. Atchison, a young American of 21 years, is the first patient to receive this revolutionary treatment, after being stranded product of an auto accident last September.

Atchinson According account, after the crash and to receive all emergency care at a medical center in Alabama (the town where he was studying nursing), was transferred to Shepherd Center in Atlanta, a place that specializes in spinal cord injury.

's where the medical team identified that Atchison was the ideal patient to receive the innovative treatment, therapy should be administered to a person who had been paralyzed from the chest to the bottom of body, and injection of embryonic stem cells in the wound area should be carried out between seven and 14 days after the injury occurs, among other requirements.

With a team of specially trained to treat (the laboratory Geron trained seven U.S. centers to implement the procedure), the patient received about 2 million stem cells into his spine, which, according to previous studies in laboratory mice, " become oligodendritos achieved, cells that produce myelin, a substance that covers the motor neurons and which enables the brain nerve impulses travel to the extremities and causing movement the body.

In research conducted by the University of California-Irvine in 2005, paralyzed mice were able to regain their mobility. The same is expected for this young man, who said in the interview with the U.S., which remains optimistic about the treatment, although so far experienced no major changes. "It's too early to talk about it," says Atchison.

Logitech Mouseman M Cw47

More evidence that pregnancy

is safe with multiple sclerosis

Reuters 08/04/2011
By Amy Norton
A review of studies strengthens the evidence that women with multiple sclerosis (MS) have the same opportunity as other healthy pregnancies and without putting your health at risk.

The findings, published in BJOG, supports the general advice that if the disease is controlled, patients may become pregnant. "A woman with MS may think about getting pregnant as the rest," said Yara D. Fragoso, a neurologist at Universidad Metropolitana Santos, Brazil, and lead author of the study.

MS is a nerve disorder that appear when the immune system mistakenly attacks nerve fibers. Symptoms include muscle weakness, numbness, vision problems and difficulty coordinating movement and balance.

Fragoso team met 22 international studies from the 1980 on a total of over 13,000 women. By combining the results found that crises were not so common symptoms during pregnancy and increased slightly for a time after birth.

But during pregnancy, and in the 12 months before and after, the rate of appearance of symptoms (relapse) never exceeded one per year. Relapses of MS increase for several months after delivery. But that does not increase the future risk of developing disability.

The team found that women with MS had higher risks than their peers to miscarriage, premature delivery, having a baby with low birth weight or having a baby with a congenital malformation.

For example, among countries, rates of preterm birth varied between 9 and 11 of every 100 live births, as in the general population.

Fragoso told Reuters Health in an e-mail that MS would have "a negative effect on pregnancy and / or the baby or the pregnancy would adversely affect the course of the disease in future."

is important that women with MS talk with their doctor when they want to become pregnant because it may need to stop the drug. The disease-modifying drugs are not approved for use in pregnancy and studies suggest that, at least interferon beta, would be associated with spontaneous abortion.
During pregnancy, the neurologist and obstetrician should work together, said Fragoso.

SOURCE: BJOG, online March 15, 2011.

How Long For 500 Mg Levaquin To Work

Seville and Stockholm Experts

demonstrate the role of a

enzyme to stop

brain swelling

Professors at the University of Seville and the Karolinska Institute in Stockholm, José Luis Venero and Bertrand Joseph, have published a recent study neurodegenerative diseases in the prestigious American journal Nature. The research focuses on the process of brain inflammation, which is closely related to the development of such diseases mainly in adults.

EUROPA PRESS. 04.04.2011

The article, 'Caspase signaling controls microglial activation and neurotoxicity', decodes and provides some of the keys involved in the process of brain inflammation, "a mechanism closely related to neurodegeneration and thus with the emergence of diseases such as senile dementia, Alzheimer's, Parkinson's or amyotrophic lateral sclerosis, demonstrating the role of enzymes (caspases) to stop the process of brain inflammation, "according to Andalucía Innova.

" There are sharply contrasting evidence in the literature scientifically demonstrate the importance of brain inflammation in these diseases. These represent a health problem of first magnitude, especially as the population grows older, "says Professor of Biochemistry and Molecular Biology, University of Sevilla, José Luis Venero.

Alzheimer's or multiple sclerosis are currently progressive and chronic diseases that require long-term treatment. Brain inflammation, responsible for such diseases is mediated by a central nervous system cells called microglia. They are responsible to remove cell debris when neuronal damage occurs in the brain.

"For example, if a problem occurs in neurons, microglia cells are activated in order to eliminate the remaining vestiges of the process. This is the normal mechanism cell performance, "says the researcher. In people suffering from neurodegenerative diseases, where the effects are growing, the problem lies in the excessive activation of microglial cells." The problem arises when these cells are overactive. In this case generate a neurotoxic environment, starting a vicious cycle of neuronal death and activation, "said Venero.

The main contribution of this paper is to demonstrate how enzymes called caspases involved in the activation process microgial, and how the use of inhibitors such enzymes may slow the effects of the diseases caused by neurodegenerative diseases.

"They are important because they play a decisive role in the stimulation of microglia and neurotoxicity associated with this process. If we can reduce the activation of these cells through caspases, could mitigate brain inflammation processes, "he argues.

The study has already been successfully tested in samples of human brain banks, which means one step closer to the first Experiments conducted in cell culture and in laboratory animals like mice. This will open up new avenues for the pharmacological treatment of these diseases, with all that means to advance the field of neurodegeneration.

"In research, sometimes a small step is a major advance in the knowledge that can also generate a large impact on society," concludes the researcher Venero.

Red Bridge Card Driver

Mirabegron, new drug

in development for bladder

overactive

The results of two phase III trials presented at the Congress of the European Association of Urology, showing improving significantly urinary incontinence and urinary frequency.

Mirabegron, the first of a new class of compounds in development for the treatment of overactive bladder, has been shown in two phase III clinical trials to significantly improve key symptoms of disease: urinary incontinence and frequency of urination. For the first time, Astellas Pharma presented these results at the XXVI Annual Congress of the European Association of Urology held in Vienna.

After 12 weeks of treatment with once daily mirabegron, there was a significant improvement compared to baseline in the two co-primary endpoints: incontinence episodes in 24 hours and number voiding in 24 hours, compared with the placebo group. Also seen significant improvements in key secondary endpoints: incontinence episodes in 24 hours and number of voids in 24 hours in the fourth week of treatment and the volume voiding of urine at the final visit. In both studies, mirabegron was well tolerated with low side effects.

"The findings of these studies are very encouraging. Mirabegron could represent the first oral drug treatment for overactive bladder with an entirely new mechanism of action from the marketing of oxybutynin for decades and, if approved, would represent the first agonist beta-3 adrenergic receptors to market " says Dr. Vik Khullar, St. Mary's Hospital at Imperial College London and lead investigator of the European-Australian Phase III.

The researcher added that, "unlike the antimuscarinics, mirabegron works by enhancing the storage capacity of the bladder. As noted in these two studies, the drug may provide an alternative and effective new treatment for OAB patients who continue to experience bothersome symptoms of incontinence and frequent urination. "

Mirabegron is a potent and selective agonist of beta adrenergic receptor-3 (β3-AR) that activates muscle β3-AR detrusor of the bladder for easy filling and urine storage. It was developed by Astellas, whose drug solifenacin (Vesicare) is currently one of the most widely used treatments for overactive bladder.

"Vesicare has provided health benefits for people with OAB around the world since it was first marketed in 2004, while mirabegron, with a different mode of action, Vesicare complements and is an important addition to our portfolio of urology drugs, "says Masafumi Nogimori, president and CEO of Astellas Pharma Inc.

New data from phase III trials confirm and corroborate the findings of dose-finding studies in phase II and smaller, in which significant improvement was observed in a wide range of symptoms of OAB, including incontinence episodes and frequency of micción.6, 7

"By improving the symptoms through its action on beta-3 receptors, mirabegron offers a completely different approach to the existing treatment of OAB and this may be good news for the large number of patients who fail to achieve the right balance of efficacy and tolerability to currently available treatments for OAB, "says Dr. Victor Nitti, the NYU Langone Medical Center in New York, USA. UU., And principal investigator in phase III U.S. trial.

Astellas submitted a marketing authorization application for mirabegron in Japan in June 2010 and plans to submit to the FDA and the EMA from July to September 2011.

JANO.es · April 4